These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12487061)

  • 41. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.
    Hermiston TW; Kuhn I
    Cancer Gene Ther; 2002 Dec; 9(12):1022-35. PubMed ID: 12522441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells.
    Campbell SA; Gromeier M
    Onkologie; 2005 Apr; 28(4):209-15. PubMed ID: 15840970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.
    Kirn D
    Expert Opin Biol Ther; 2001 May; 1(3):525-38. PubMed ID: 11727523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond.
    Kaufmann JK; Nettelbeck DM
    Trends Mol Med; 2012 Jul; 18(7):365-76. PubMed ID: 22633438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
    Schirrmacher V; Fournier P
    Methods Mol Biol; 2009; 542():565-605. PubMed ID: 19565923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
    Wildner O
    Curr Opin Mol Ther; 2003 Aug; 5(4):351-61. PubMed ID: 14513677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncolytic viruses for potential osteosarcoma therapy.
    Hingorani P; Sampson V; Lettieri C; Kolb EA
    Adv Exp Med Biol; 2014; 804():259-83. PubMed ID: 24924179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
    Nguyen TL; Wilson MG; Hiscott J
    Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Employing tumor hypoxia for oncolytic therapy in breast cancer.
    Chun YS; Adusumilli PS; Fong Y
    J Mammary Gland Biol Neoplasia; 2005 Oct; 10(4):311-8. PubMed ID: 16826462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
    Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
    Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity.
    Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG
    Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of suicide genes for cancer gene therapy: study of the different approaches.
    Vassaux G; Martin-Duque P
    Expert Opin Biol Ther; 2004 Apr; 4(4):519-30. PubMed ID: 15102601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction.
    Campbell SA; Gromeier M
    Onkologie; 2005 Mar; 28(3):144-9. PubMed ID: 15772465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
    Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
    Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Viral vectors for cancer gene therapy: viral dissemination and tumor targeting.
    Jia W; Zhou Q
    Curr Gene Ther; 2005 Feb; 5(1):133-42. PubMed ID: 15638717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
    Yu DC; Working P; Ando D
    Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.